Evidence map›Paper›PMID 36346688›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group.

David Milewski, Hyun Jung, G Thomas Brown, Yanling Liu, Ben Somerville, Curtis Lisle, Marc Ladanyi, Erin R Rudzinski, Hyoyoung Choo-Wosoba, Donald A Barkauskas and 15 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Rhabdomyosarcoma in children and young adults.Virchows Archiv : an international journal of pathology · 2025
    Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 12 institutions in 2 countries.

David Milewski *Genetics Branch, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-9778-8548
Hyun Jung *Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0001-7467-8189
G Thomas Brown *Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0001-7383-3116
Yanling LiuAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-5173-2426
Ben SomervilleGenetics Branch, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-3222-4979
Curtis LisleAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0003-4056-3038
Marc LadanyiDepartment of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.ORCID 0000-0001-9055-7213
Erin R RudzinskiDepartment of Laboratories, Seattle Children's Hospital, Seattle, Washington.ORCID 0000-0002-7591-956X
Hyoyoung Choo-WosobaBiostatistics and Data Management Section, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-8756-1016
Donald A BarkauskasDepartment of Population and Public Health Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-2339-719X
Tammy LoChildren's Oncology Group, Monrovia, California.ORCID 0000-0002-7980-9595
David HallChildren's Oncology Group, Monrovia, California.ORCID 0000-0003-1257-2316
Corinne M LinardicDepartments of Pediatrics and Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, North Carolina.ORCID 0000-0002-3257-2885
Jun S WeiGenetics Branch, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-4812-0250
Hsien-Chao ChouGenetics Branch, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-4870-9663
Stephen X SkapekDepartment of Pediatrics, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-4136-8384
Rajkumar VenkatramaniDivision of Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-4785-106X
Peter K BodeInstitut für Pathologie, Kantonsspital Winterthur, Winterthur, Switzerland.ORCID 0000-0002-9633-4042
Seth M SteinbergBiostatistics and Data Management Section, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-8280-551X
George ZakiCancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0002-2740-3307
Igor B KuznetsovDepartment of Epidemiology & Biostatistics, School of Public Health, University at Albany, Rensselaer, New York.ORCID 0000-0003-3741-8964
Douglas S HawkinsChair of Children's Oncology Group, Department of Pediatrics, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington.ORCID 0000-0003-3602-1375
Jack F ShernPediatric Oncology Branch, Center for Cancer Research, NIH, Bethesda, Maryland.ORCID 0000-0001-5579-7625
Jack CollinsAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, Maryland.ORCID 0000-0001-8281-2085
Javed KhanGenetics Branch, NCI, NIH, Bethesda, Maryland.ORCID 0000-0002-5858-0488
National Institutes of Health · USFrederick National Laboratory for Cancer Research · USChildren's Oncology Group · CHSeattle Children's Hospital · USUniversity of Southern California · USCenter for Cancer Research · USChildren's Cancer Center · USDuke University · USKantonsspital Winterthur · CHMemorial Sloan Kettering Cancer Center · USThe University of Texas Southwestern Medical Center · USUniversity at Albany, State University of New York · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Infectious Diseases Research Technologies Core - BethesdaZICAI001051 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$226.1M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI ANDERSON, JAMES R · 2003 to 2013
$67.5M
Office of Collaborative BiostatisticsZIDSC007202 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI CHOO-WOSOBA, HYOYOUNG · 2009 to 2025
$14.5M
BIOINFORMATICS: SYSTEMS BIOLOGY OF PEDIATRIC CANCERSZIABC011002 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$9.3M
Screening for Cys-Reactive Ligands to Target PAX3-FOXO1U54CA231630 · NCI · DUKE UNIVERSITY · PI LINARDIC, CORINNE MARY · 2019 to 2023
$6.5M
Predicting Response Prognosis in Pediatric CancersZIASC010366 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI KHAN, JAVED · 2009 to 2025
$4.7M
Intramural NIH HHS ZIA BC011002NCI NIH HHS HHSN261201500003CNCI NIH HHS HHSN261201500003INCI NIH HHS P30 CA008748NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U54 CA231630
6 · The paper itself

Abstract

purposeRhabdomyosarcoma (RMS) is an aggressive soft-tissue sarcoma, which primarily occurs in children and young adults. We previously reported specific genomic alterations in RMS, which strongly correlated with survival; however, predicting these mutations or high-risk disease at diagnosis remains a significant challenge. In this study, we utilized convolutional neural networks (CNN) to learn histologic features associated with driver mutations and outcome using hematoxylin and eosin (H&E) images of RMS. EXPERIMENTAL

designDigital whole slide H&E images were collected from clinically annotated diagnostic tumor samples from 321 patients with RMS enrolled in Children's Oncology Group (COG) trials (1998-2017). Patches were extracted and fed into deep learning CNNs to learn features associated with mutations and relative event-free survival risk. The performance of the trained models was evaluated against independent test sample data (n = 136) or holdout test data.

resultsThe trained CNN could accurately classify alveolar RMS, a high-risk subtype associated with PAX3/7-FOXO1 fusion genes, with an ROC of 0.85 on an independent test dataset. CNN models trained on mutationally-annotated samples identified tumors with RAS pathway with a ROC of 0.67, and high-risk mutations in MYOD1 or TP53 with a ROC of 0.97 and 0.63, respectively. Remarkably, CNN models were superior in predicting event-free and overall survival compared with current molecular-clinical risk stratification.

conclusionsThis study demonstrates that high-risk features, including those associated with certain mutations, can be readily identified at diagnosis using deep learning. CNNs are a powerful tool for diagnostic and prognostic prediction of rhabdomyosarcoma, which will be tested in prospective COG clinical trials.

Indexed as

Deep LearningRhabdomyosarcomaRhabdomyosarcoma, AlveolarChildEosine Yellowish-(YS)HematoxylinHumansPaired Box Transcription FactorsPAX3 Transcription FactorPAX7 Transcription FactorProspective StudiesYoung AdultEosine Yellowish-(YS)HematoxylinPaired Box Transcription FactorsPAX3 protein, humanPAX3 Transcription FactorPAX7 protein, humanPAX7 Transcription Factor

Identifiers

PMID36346688
PMCPMC9843436
OpenAlexW4308523788

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.